NDA 210296 · Banner Life Sciences
Bafiertam
Monomethyl Fumarate · Oral
Last checked: Nov 19, 2026Latest source record: Sep 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Apr 28, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
80
4 Phase 3, 14 recruiting
FAERS reports
935
127 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 16, 2026.
BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Mechanism: The mechanism by which monomethyl fumarate (MMF) exerts its therapeutic effect in multiple sclerosis is unknown. MMF has been shown to activate the Nuclear factor (erythroid-derived 2) like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BAFIERTAM · MONOMETHYL FUMARATE 95MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Monomethyl" as an intervention, any sponsor and status, largest first.
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07720284 · 915 participants (planned) · Start Jul 16, 2026 · Primary completion Sep 11, 2030
Drug: Dato-DXd; Rilvegostomig and 4 more · For: High-risk Muscle Invasive Urothelial Carcinoma
Sites: Hot Springs, Arkansas; Little Rock, Arkansas; San Francisco, California · 160 sites in all
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT03535298 · 800 participants (planned) · Start Jan 3, 2019 · Primary completion Jul 30, 2027
Drug: Early Highly Effective Therapies Group; Escalation Therapies Group · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Aurora, Colorado; Minneapolis, Minnesota; Rochester, Minnesota · 30 sites in all
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.Industry
NCT03181984 · 501 participants · Start Aug 31, 2017 · Primary completion Apr 19, 2023
Drug: Hemoporfin · For: Port-Wine Stain
Sites: Harbin, China; Shijiazhuang, China; Wuxi, China · 7 sites in all
- ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell LymphomasPivotal-lookingCompleted
Seagen Inc.Pfizer (PFE)
NCT01777152 · 452 participants · Start Jan 31, 2013 · Primary completion Aug 15, 2018
Drug: brentuximab vedotin; doxorubicin and 3 more · For: Anaplastic Large-Cell Lymphoma; Non-Hodgkin Lymphoma; T-Cell Lymphoma
Sites: Gilbert, Arizona; Duarte, California; Stanford, California · 144 sites in all
D. Walter WrayAcademic, hospital or other
NCT02966665 · 420 participants (planned) · Start Sep 2008 · Primary completion Aug 2030
Drug: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate; BQ-123 and 3 more · For: Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure and 1 more
Sites: Salt Lake City, Utah
- FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerPivotal-lookingStatus unknown
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT05755048 · 314 participants (planned) · Start Mar 28, 2023 · Primary completion Jul 30, 2025
Drug: Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502); Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) · For: Breast Cancer
Sites: Bengbu, China; Hefei, China; Beijing, China · 56 sites in all
LigaChem Biosciences, Inc.Industry
NCT05941507 · 300 participants (planned) · Start Oct 5, 2023 · Primary completion Jan 2027
Drug: LCB84; Anti-PD-1 monoclonal antibody · For: Advanced Solid Tumors
Sites: Los Angeles, California; Boston, Massachusetts; Ann Arbor, Michigan · 8 sites in all
Seagen Inc.Pfizer (PFE)
NCT01969643 · 290 participants · Start Oct 22, 2013 · Primary completion Feb 4, 2023
Drug: ladiratuzumab vedotin; Trastuzumab · For: HER2 Positive Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Triple Negative Breast Neoplasms and 1 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; La Jolla, California · 38 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- flushing350
- pruritus110
- product dose omission issue83
- nausea76
- abdominal discomfort65
- erythema65
- abdominal pain upper51
- fatigue47
- diarrhoea46
- rash44
- dizziness43
- paraesthesia43
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 73 |
| 2022 | 227 |
| 2023 | 166 |
| 2024 | 318 |
| 2025 | 110 |
| 2026 | 39 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bafiertam (Monomethyl Fumarate)
2024 spending
$8.2M
Beneficiaries
172
999 claims
Per beneficiary
$47,919
$54.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $767,710 |
| 2022 | $3,109,005 |
| 2023 | $4,951,676 |
| 2024 | $8,241,991 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
Camidge DR, Bar J, Horinouchi H, et al. · J Clin Oncol 2024 · Clinical Trial, Phase II, Multicenter Study
- EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
Rosenberg J, Sridhar SS, Zhang J, et al. · J Clin Oncol 2020 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma.
Lee V, Hultcrantz M, Petrone S, et al. · JAMA Ophthalmol 2025 · Clinical Trial, Phase III, Multicenter Study
- Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
Deng R, Gibiansky L, Lu T, et al. · CPT Pharmacometrics Syst Pharmacol 2024 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
Sheng X, Wang L, He Z, et al. · J Clin Oncol 2024 · Clinical Trial, Phase II, Multicenter Study
- Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
McDermott MSJ, O'Brien NA, Hoffstrom B, et al. · Clin Cancer Res 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Banner Life Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.